Literature DB >> 28938477

Growth Hormone and the Epithelial-to-Mesenchymal Transition.

Alison L Brittain1,2, Reetobrata Basu1, Yanrong Qian1, John J Kopchick1,2.   

Abstract

Context: Previous studies have implicated growth hormone (GH) in the progression of several cancers, including breast, colorectal, and pancreatic. A mechanism by which GH may play this role in cancer is through the induction of the epithelial-to-mesenchymal transition (EMT). During the EMT process, epithelial cells lose their defining phenotypes, causing loss of cellular adhesion and increased cell migration. This review aims to carefully summarize the previous two decades of research that points to GH as an initiator of EMT, in both cancerous and noncancerous tissues. Evidence Acquisition: Sources were collected using PubMed and Google Scholar search engines by using specific GH- and/or EMT-related terms. Identified manuscripts were selected for further analysis based on presentation of GH-induced molecular markers of the EMT process in vivo or in vitro. Evidence Synthesis: Cellular mechanisms involved in GH-induced EMT are the focus of this review, both in cancerous and noncancerous epithelial cells. Conclusions: Our findings suggest that a myriad of molecular mechanisms are induced by GH that cause EMT and may point to potential therapeutic use of GH antagonists or any downregulator of GH action in EMT-related disease.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28938477     DOI: 10.1210/jc.2017-01000

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  Growth hormone in the tumor microenvironment.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Arch Endocrinol Metab       Date:  2019 Nov-Dec       Impact factor: 2.309

Review 2.  Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer.

Authors:  A J Fritz; N E Gillis; D L Gerrard; P D Rodriguez; D Hong; J T Rose; P N Ghule; E L Bolf; J A Gordon; C E Tye; J R Boyd; K M Tracy; J A Nickerson; A J van Wijnen; A N Imbalzano; J L Heath; S E Frietze; S K Zaidi; F E Carr; J B Lian; J L Stein; G S Stein
Journal:  Genes Chromosomes Cancer       Date:  2019-03-15       Impact factor: 5.006

3.  Excess growth hormone suppresses DNA damage repair in epithelial cells.

Authors:  Vera Chesnokova; Svetlana Zonis; Robert Barrett; Hiraku Kameda; Kolja Wawrowsky; Anat Ben-Shlomo; Masaaki Yamamoto; John Gleeson; Catherine Bresee; Vera Gorbunova; Shlomo Melmed
Journal:  JCI Insight       Date:  2019-02-07

Review 4.  Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer.

Authors:  John J Kopchick; Reetobrata Basu; Darlene E Berryman; Jens O L Jorgensen; Gudmundur Johannsson; Vishwajeet Puri
Journal:  Nat Rev Endocrinol       Date:  2022-06-24       Impact factor: 47.564

5.  Exogenous growth hormone promotes an epithelial-mesenchymal hybrid phenotype in cancerous HeLa cells but not in non-cancerous HEK293 cells.

Authors:  E M Olascoaga-Caso; E Tamariz-Domínguez; J C Rodríguez-Alba; E Juárez-Aguilar
Journal:  Mol Cell Biochem       Date:  2022-10-12       Impact factor: 3.842

6.  Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma in vivo.

Authors:  Reetobrata Basu; Yanrong Qian; Samuel Mathes; Joseph Terry; Nathan Arnett; Trent Riddell; Austin Stevens; Kevin Funk; Stephen Bell; Zac Bokal; Courtney Batten; Cole Smith; Isaac Mendez-Gibson; Silvana Duran-Ortiz; Grace Lach; Patricia Alexandra Mora-Criollo; Prateek Kulkarni; Emily Davis; Elizabeth Teaford; Darlene E Berryman; Edward O List; Sebastian Neggers; John J Kopchick
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

7.  A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis.

Authors:  Hong Pan; Huanrong Diao; Wen Zhong; Taifang Wang; Ping Wen; Chunli Wu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 8.  Targeting growth hormone function: strategies and therapeutic applications.

Authors:  Man Lu; Jack U Flanagan; Ries J Langley; Michael P Hay; Jo K Perry
Journal:  Signal Transduct Target Ther       Date:  2019-02-08

Review 9.  Dual Characters of GH-IGF1 Signaling Pathways in Radiotherapy and Post-radiotherapy Repair of Cancers.

Authors:  Yunyun Cheng; Wanqiao Li; Ruirui Gui; Chunli Wang; Jie Song; Zhaoguo Wang; Xue Wang; Yannan Shen; Zhicheng Wang; Linlin Hao
Journal:  Front Cell Dev Biol       Date:  2021-06-09

Review 10.  Growth Hormone (GH) and Gonadotropin-Releasing Hormone (GnRH) in the Central Nervous System: A Potential Neurological Combinatory Therapy?

Authors:  Carlos G Martínez-Moreno; Denisse Calderón-Vallejo; Steve Harvey; Carlos Arámburo; José Luis Quintanar
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.